Clinical Trials Directory

Trials / Conditions / Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Cancer

12 registered clinical trials studyying Esophageal Squamous Cell Cancer — 3 currently recruiting.

StatusTrialSponsorPhase
Enrolling By InvitationA Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid T
NCT07218003
Rondo TherapeuticsPhase 1
RecruitingStudy of XB010 in Subjects With Solid Tumors
NCT06545331
ExelixisPhase 1
RecruitingLymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
NCT06596954
Ruijin HospitalN/A
Active Not RecruitingPhase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823
Taiho Oncology, Inc.Phase 2
TerminatedToripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
NCT04804696
Peking UniversityPhase 2
TerminatedMetabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment R
NCT03223662
National Cancer Institute (NCI)Phase 2
UnknownSequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell
NCT02016287
Shen LinPhase 2
UnknownSequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamo
NCT02016274
Shen LinPhase 2
UnknownStudy of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
NCT01993784
Peking UniversityPhase 1 / Phase 2
TerminatedCisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous
NCT01627379
AIO-Studien-gGmbHPhase 3
CompletedA Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
NCT01351103
Novartis PharmaceuticalsPhase 1
UnknownNimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
NCT01336049
Peking UniversityPhase 2